Genomma Lab InternacionalB de CVMEX:LABB +2.59%66 Net Current Asset Value is MXN0.59 as of Mar. 2026, which is 100% below its 10-year median of 69.40. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 614 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks worse than 87.3% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Net Current Asset Value or its related term are showing as below:
MEX:LABB'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 19.86 Med: 69.4 Max: 483.67
Current: 25.49
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Genomma Lab InternacionalB de CV was 483.67. The lowest was 19.86. And the median was 69.40.
MEX:LABB's Price-to-Net-Current-Asset-Value is ranked worse than 87.3% of 614
companies
in the Drug Manufacturers industry
Industry Median: 5.305
vs MEX:LABB: 25.49
Genomma Lab InternacionalB de CV (MEX:LABB) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Genomma Lab InternacionalB de CV Net Current Asset Value Related Terms
Genomma Lab InternacionalB de CV Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Net Current Asset Value Chart
MEX:LABB vs ZTS, UTHR, VTRS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of MXN0.59 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Net Current Asset Value of MXN0.59 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 99% below median its historical median of 69.40. Over the past decade, Genomma Lab InternacionalB de CV's Net Current Asset Value has ranged from 19.86 to 483.67. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #536 out of 614 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is Genomma Lab InternacionalB de CV's Net Current Asset Value too high?
Genomma Lab InternacionalB de CV's current Net Current Asset Value of MXN0.59 is 99% below median its 10-year median of 69.40. Over the past 10 years, this metric has ranged from a low of 19.86 to a high of 483.67. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #536 out of 614 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #536 out of 614 companies for Net Current Asset Value. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Net Current Asset Value is 5.31. Historically, Genomma Lab InternacionalB de CV's own Net Current Asset Value has ranged from 19.86 to 483.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.31, based on 614 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Net Current Asset Value is MXN0.59, which is 99% below median its own 10-year median of 69.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current Net Current Asset Value is MXN0.59, which is 99% below median its 10-year median of 69.40. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Net Current Asset Value is MXN0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Net Current Asset Value: MXN0.59 (99% below median its 10-year median of 69.40)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
